| Acetylcysteine IV in Acute Paracetamol Overdose
|
SESLHDPR/566 |
|
| Acetylcysteine IV in non-paracetamol induced acute liver injury failure
|
|
|
| Adenosine Protocol – Antiarrhythmic
|
SESLHDPR/583 |
|
| Agomelatine in major depression
|
SESLHDPR/646 |
|
| Apixaban
|
SESLHDPR/588 |
|
| Argatroban for Heparin Induced Thrombocytopenia (HIT)
|
SESLHDPR/719 |
|
| Aspirin IV in Neurointerventional Procedures and Intensive Care Areas
|
SESLHDPR/700 |
|
| Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis
|
SESLHDPR/699 |
|
| Bedaquiline fumarate for resistant pulmonary tuberculosis
|
SESLHDPR/672 |
|
| Belatacept for prophylaxis of organ rejection in adult patients receiving/received a kidney transplant
|
SESLHDPR/751 |
|
| Bivalirudin for Heparin induced thrombocytopenia (HIT)
|
SESLHDPR/711 |
|
| Caplacizumab for severe thrombotic thrombocytopenic purpura
|
SESLHDPR/713 |
|
| Ceftaroline fosamil
|
SESLHDPR/654 |
|
| Ceftazidime-Avibactam
|
SESLHDPR/698 |
|
| Ceftolozane/tazobactam
|
SESLHDPR/655 |
|
| Colistimethate (Colistin) IV (Polymyxin E) for Urinary Tract Infections
|
SESLHDPR/608 |
|
| Dabigatran
|
SESLHDPR/589 |
|
| Danaparoid - Safe Use of
|
SESLHDPR/600 |
|
| Dinoprostone
|
SESLHDPR/568 |
|
| Empaglifozin for Type 2 Diabetes
|
SESLHDPR/599 |
|
| Entecavir for HBV reactivation in Renal Patients
|
SESLHDPR/726 |
|
| Evolocumab for familial hypercholesterolaemia
|
SESLHDPR/594 |
|
| Fentanyl 2microg/mL with Adrenaline (epinephrine) 2 microg/mL and Bupivacaine 0.1% epidural infusion
|
SESLHDPR/637 |
|
| Fidaxomicin for treatment of confirmed Clostridioides difficile infection (CDI) in adults
|
SESLHDPR/710 |
|
| Fomepizole for treatment of toxic alcohol (methanol, ethylene glycol) poisoning
|
SESLHDPR/689 |
|
| Fondaparinux for Heparin induced Thrombocytopenia (HIT)
|
SESLHDPR/716 |
|
| Fosfomycin Oral Prescribing Protocol
|
SESLHDPR/661 |
|
| Glargine - Safe Use of High Concentration Insulin Glargine 300 units/mL (Toujeo®)
|
SESLHDPR/638 |
|
| Idarucizumab in Urgent Dabigatran Reversal
|
SESLHDPR/571 |
|
| Levosimendan
|
SESLHDPR/725 |
|
| Lidocaine (lignocaine) patch for symptomatic treatment of neuropathic pain refractory or unsuitable for alternative medications
|
SESLHDPR/648 |
|
| Meglumine Diatrizoate and Sodium Diatrizoate (Gastrografin®) in Adult Adhesional Small Bowel Obstruction
|
SESLHDPR/570 |
|
| Micafungin for prevention and treatment of fungal infections in critically ill patients
|
SESLHDPR/630 |
|
| Naltrexone for treatment of long-acting opioid poisoning
|
SESLHDPR/651 |
|
| Ocrelizumab for Multiple Sclerosis
|
SESLHDPR/629 |
|
| Paracetamol
|
SESLHDPR/717 |
|
| Phentolamine in the treatment of dermal necrosis or sloughing following extravasation of peripherally administered noradrenaline (norepinephrine)
|
SESLHDPR/602 |
|
| Polymyxin B IV for infections outside of the urinary tract
|
SESLHDPR/573 |
|
| Ravulizumab
|
SESLHDPR/684 |
|
| Rituximab
|
|
|
| Rivaroxaban
|
SESLHDPR/601 |
|
| Ryzodeg® - Insulin degludec/insulin aspart (Ryzodeg® 70/30) Prescribing Protocol
|
SESLHDPR/650 |
|
| Sacubitril+Valsartan (Entresto®) for Systolic Heart Failure
|
SESLHDPR/585 |
|
| Siponimod in the treatment of secondary progressive MS (SPMS)
|
SESLHDPR/703 |
|
| Sodium Thiosulfate in Calciphylaxis
|
SESLHDPR/659 |
|
| Standard short-course therapy for Tuberculosis (TB) with Fixed Dose Combination tablets
|
SESLHDPR/657 |
|
| Subcutaneous furosemide (frusemide) for end stage heart failure with fluid overload in the dying patient
|
SESLHDPR/691 |
|
| Subcutaneous levetiracetam for seizure management in palliative care patients
|
SESLHDPR/692 |
|
| Subcutaneous levomepromazine for refractory nausea in the palliative care patient and agitation in the terminal phase
|
SESLHDPR/693 |
|
| Subcutaneous lidocaine (lignocaine) for refractory neuropathic pain in the palliative care setting
|
SESLHDPR/694 |
|
| Subcutaneous phenobarbital for refractory terminal agitation and uncontrolled seizures (including status epilepticus) in the imminently dying patient
|
SESLHDPR/695 |
|
| Tapentadol in Moderate to Severe Pain
|
SESLHDPR/587 |
|
| Ticagrelor – Prevention of thrombotic complications post neurointerventional stenting procedures
|
SESLHDPR/673 |
|
| Tolvaptan in inpatient treatment of hyponatraemia
|
SESLHDPR/576 |
|
| Ulipristal Acetate for Emergency Contraception
|
SESLHDPR/619 |
|
| Ustekinumab for Crohn's Disease
|
SESLHDPR/611 |
|
| Varenicline for smoking cessation
|
SESLHDPR/649 |
|
| Zoledronic Acid for Early/Locally Advanced Breast Cancer
|
|
|
| Zoledronic Acid in the treatment of Osteoporosis with fracture due to minimal trauma
|
SESLHDPR/720 |
|
